CCND1 and neoplasm: Luteolin-7-O-β-D-glucoside, present at 5.27% in the BESD and 4.64% in the BF1SD, inhibits tumor proliferation by blocking the activation of the NF-κB transcription factor and modulating cyclin D1 expression, thereby slowing cell cycle progression [27].